Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on oncology, developing antibody therapeutics targeting the immune system to fight cancer. The company became publicly traded through a merger with Brookline Capital Acquisition Corp, a blank-check company sponsored by Brookline Capital, which completed its SPAC IPO in 2021. The 10-Q filed on August 16, 2021, under accession number 0001193125-21-247790 reflects the company's early post-combination reporting obligations as a public entity. Apexigen's pipeline has centered on CD40 agonist antibody candidates designed to activate immune responses against tumors. Visit SpacDesk and sign up for full data, filings, and deal analytics on Apexigen and hundreds of other SPAC transactions.